U.S. markets open in 1 hour 20 minutes
  • S&P Futures

    4,407.00
    -7.25 (-0.16%)
     
  • Dow Futures

    34,948.00
    -86.00 (-0.25%)
     
  • Nasdaq Futures

    15,119.00
    +1.25 (+0.01%)
     
  • Russell 2000 Futures

    2,202.80
    -10.60 (-0.48%)
     
  • Crude Oil

    71.89
    -0.02 (-0.03%)
     
  • Gold

    1,798.80
    -0.40 (-0.02%)
     
  • Silver

    25.24
    -0.08 (-0.33%)
     
  • EUR/USD

    1.1811
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.2760
    0.0000 (0.00%)
     
  • Vix

    18.58
    +1.38 (+8.02%)
     
  • GBP/USD

    1.3809
    -0.0015 (-0.11%)
     
  • USD/JPY

    110.0870
    -0.2880 (-0.26%)
     
  • BTC-USD

    37,834.98
    -611.56 (-1.59%)
     
  • CMC Crypto 200

    899.74
    -15.75 (-1.72%)
     
  • FTSE 100

    6,997.94
    -27.49 (-0.39%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Biohaven Pharmaceuticals Looks Ready to Trade Higher

·2 min read
Biohaven Pharmaceuticals Looks Ready to Trade Higher

For his final "Executive Decision" segment of Tuesday's Mad Money program, Jim Cramer checked in with Dr. Vlad Coric, CEO of Biohaven Pharmaceuticals , which on Tuesday received FDA approval to use its drug Nurtec ODT for the prevention of migraine. Coric said they've been working for years to get to today, where they can offer patients one pill for both the treatment and prevention of migraine. Coric added that prevention is critically important because most patients know what their triggers are and know when migraine is about to hit.